NR2B-Selective N-Methyl-D-aspartate Antagonists: Synthesis and Evaluation of 5-Substituted Benzimidazoles

Journal of Medicinal Chemistry

Volumn 47, Issue 8, 2004, Pages 2089-2096

  McCauley, John A ^a   Theberge, Cory R ^a   Romano, Joseph J ^a   Billings, Susan B ^a   Anderson, Kenneth D ^a   Claremon, David A ^a   Freidinger, Roger M ^a   Bednar, Rodney A ^a   Mosser, Scott D ^a   Gaul, Stanley L ^a   Connolly, Thomas M ^a   Condra, Cindra L ^a   Xia, Menghang ^a   Cunningham, Michael E ^a   Bednar, Bohumil ^a   Stump, Gary L ^a   Lynch, Joseph J ^a   Macaulay, Alison ^b   Wafford, Keith A ^b   Koblan, Kenneth S ^a   Liverton, Nigel J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[4 (2 FLUOROBENZYL)PIPERIDIN 1 YL]METHYL]BENZIMIDAZOL 5 OL; ALPHA 1 ADRENERGIC RECEPTOR; BENZIMIDAZOLE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HYPERALGESIA; INHIBITION KINETICS; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; BENZIMIDAZOLES; BRAIN; CALCIUM; CARRAGEENAN; CELL LINE; DOGS; FEMALE; HUMANS; HYPERALGESIA; MALE; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 11144355020     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030483s     Document Type: Article

References (28)

1. Le, D. A.; Lipton, S. A. Potential and Current Use of N-Methyl-D-aspartate (NMDA) Receptor Antagonists in Diseases of Aging. Drugs Aging 2001, 18 (10), 717-724.
2. Max, M. B.; Byas-Smith, M. G.; Gracely, R. H. Bennet, G. J. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin. Neuropharmacol. 1995, 18, 360-368.
3. Muir, K. W.; Lees, K. R. Clinical Experience with Excitatory Amino Acid Antagonist Drugs. Stroke 1995, 26, 503-513.
4. Sugihara, H.; Moriyoshi, K.; Ishii, T.; Masu, M.; Nakanishi, S. Structures and Properties of Seven Isoforms of NMDA Receptor Generated by Alternative Splicing. Biochem. Biophys. Res. Commun. 1992, 185, 826-832.
5. Cull-Candy, S.; Brickley, S.; Farrant, M. NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 2001, 11, 327-335.
6. Monyer, H.; Burnashev, N.; Laurie, D. J.; Sakmann, B.; Seeburg, P. H. Developmental and Regional Expression in the Rat Brain and Functional Properties of Four NMDA Receptors. Neuron 1994, 12, 529.
7. Boyce, S.; Wyatt, J. K.; Webb, R.; O'Donnell, R.; Mason, G.; Rigby, M.; Sirinathsinghji, D.; Hill, R. G.; Rupniak, N. M. J. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999, 38, 611-623.
8. Williams, K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric recepters. Mol. Pharmacol, 1993, 44, 851-859.
9. Kew, J. N. C.; Trube, G.; Kemp, J. A. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J. Physiol. (London) 1996, 497 (3), 761-772.
10. Chenard, B. L.; Bordner, J.; Butler, T. W.; Chambers, L. K.; Collins, M. A.; DeCosta, D. L.; Ducat, M. F.; Dumont, M. L.; Fox, C. B.; Mena, E. E.; Menniti, F. S.; Nielsen, J.; Pagnozzi, M. J.; Richter, K. E. G.; Ronau, R. T.; Shalaby, I. A.; Stemple, J. Z.; White, W. F. (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A Potent New Neuroprotectant Which Blocks N-Methyl-D-aspartate Responses. J. Med. Chem. 1995, 38 (16), 3138-3145.
11. Pinard, E.; Alanine, A.; Bourson, A.; Buttelmann, B.; Heitz, M.P.; Mutel, V.; Gill, R.; Trube, G.; Wyler, R. 4-Aminoquinolines as a Novel Class of NR1/ 2B Subtype Selective NMDA Receptor Antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 2615-2619.
12. Wright, J. L.; Kesten, S. R.; Upasani, R. B.; Lan, N. C. 4-Benzylpiperidinylalkylsulfinyl-substituted heterocycles and their use as subtype-selective NMDA receptor antagonists. PCT Int. Appl. WO 2000000197, January 6, 2000.
13. 1-(Benzyl)cinnamamidine Derived NR2B Subtype-Selective NMDA Receptor Antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 693-696.
14. Claiborne, C. F.; McCauley, J. A.; Libby, B. E.; Curtis, N. R.; Diggle, H. J.; Kulagowski, J. J.; Michelson, S. R.; Anderson, K. D.; Claremon, D. A.; Freidinger, R. M.; Bednar, R. A.; Mosser, S. D.; Gaul, S. L.; Connolly, T. M.; Condra, C. L.; Bednar, B.; Stump, G. L.; Lynch, J. J.; Macaulay, A.; Wafford, K. A.; Koblan, K. S.; Liverton, N. J. Orally Efficacious NR2B.Selective NMDA Receptor Antagonists. Bioorg. Med. Chem. Lett. 2003,13, 697-700.
15. Chizh, B. A.; Headley, P. M.; Tzschentke, T. M. NMDA Receptor Antagonists as Analgesics: Focus on the NR2B Subtype. Trends Pharmacol. Sci. 2001, 22 (12), 636-642.
16. (a) Nikam, S. S.; Meltzer, L. T. NR2B Selective NMDA Receptor Antagonists. Curr. Pharm. Des. 2002, 8, 845-855.
17. (b) Chenard, B. L.; Menniti, F. S. Antagonists Selective for NMDA Receptors Containing the NR2B Subunit. Curr. Pharm. Des. 1999, 5, 381-404.
18. (a) Konig, W.; Geiger, R. A New Method for the Synthesis of Peptides. Chem. Ber. 1970, 103, 788-798.
19. (b) Sheehan, J. C.; Cruickshank, P. A.; Boshart, G. L. A Convenient Synthesis of Water-Soluble Carbodiimides. J. Org. Chem. 1961, 26, 2525-2528.
20. Preston, P. N. Synthesis, Reactions and Spectroscopic Properties of Benzimidazoles. Chem. Rev. 1974, 74, 279-314.
21. Rajappa, S.; Sreenivasan, R. Selective Functionalizaiton in 2-Nitro-p-phenylenediamine. Indian J. Chem., Sect. B 1980, 19B(7), 533-535.
22. Bhattacharya, A. K.; Thyagarajan, T. The Michaellis-Arbuzov Rearrangement. Chem. Rev. 1981, 81, 415-430.
23. Wadsworth, W. S. Synthetic Applications of Phosphoryl-Stabilized Anions. Org. React. 1977, 25, 73-253.
24. 2+ influx assay protcols, see the following. McCauley, J. A.; Theberge, C. R.; Liverton, N. J.; Claremon, D. A.; Claiborne, C. F. 2-Benzyl and 2-Heteroaryl Benzimidazole NMDA/NR2B Antagonists. U.S. Patent 6,316,474 B1, November 13, 2001.
25. For hERG binding assay protocol, see the following. Butcher, J. W.; Claremon, D. A.; Connolly, T. M.; Dean, D. C.; Karczewski, J.; Koblan, K. S.; Kostura, M. J.; Liverton, N. J.; Melillo, D. G. Radioligand and Binding Assay. PCT Int. Appl. WO 0205860 A1, 2002.
26. For prazosin binding assay protocol, see the following. Greengrass, P.; Bremner, R. Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur. J. Pharmacol. 1979, 55, 323-326.
27. All animal studies described in this report were approved by the Merck Research Laboratories Institutional Animal Care and Use Committee.
28. Priestley, T.; Laughton, P.; Myers, J.; Le Bourdellès, B.; Kerby, J.; Whiting, P. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. Mol. Pharmacol. 1995, 48, 841-848.